Search results for " effectiveness."

showing 10 items of 256 documents

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…

medicine.medical_specialtyCirrhosisHepatologySofosbuvirCost effectivenessbusiness.industryHepatologymedicine.diseaseSurgeryQuality-adjusted life yearTelaprevirchemistry.chemical_compoundTolerabilitychemistryBoceprevirInternal medicinemedicinebusinesshealth care economics and organizationsmedicine.drugHepatology
researchProduct

Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test

2010

Objectives: The aim of this study was to compare the cost and the effectiveness of two biennial fecal occult blood screening tests for colorectal cancer: a guaiac nonrehydrated test (G-FOBT) and an immunochemical test (I-FOBT) with the absence of screening.Methods: A Markov model was developed to compare these strategies in a general population of subjects aged 50 to 74 over a 20-year period.Results: Compared with the absence of screening, G-FOBT and I-FOBT were associated with a decrease in colorectal cancer mortality of 17.4 percent and 25.2 percent, respectively. With regard to cost-effectiveness, expressed as cost per life-year gained, I-FOBT was the most effective and most costly alter…

medicine.medical_specialtyColorectal cancerCost effectivenessCost-Benefit Analysishealth care facilities manpower and serviceseducationPopulationImmunologic TestsSensitivity and SpecificityInternal medicinemedicineHumansMass ScreeningeducationSensitivity analyseshealth care economics and organizationsMass screeningAgedGynecologyeducation.field_of_studybiologybusiness.industryHealth PolicyEurosMiddle Agedmedicine.diseasebiology.organism_classificationMarkov Chainsdigestive system diseasesTest (assessment)surgical procedures operativeFecal occult blood screeningOccult BloodIndicators and ReagentsFranceColorectal NeoplasmsGuaiacbusinessInternational Journal of Technology Assessment in Health Care
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct

A Systematic Review of Cost-effectiveness Evidence of Endoscopic Saphenous Vein Harvesting: Is it Efficient?

2011

Objective: Greater saphenous vein harvest for coronary and lower extremity bypass requires the longest incision of any surgical procedure. Endoscopic vein harvest allows better results in some clinical variables compared to open harvesting techniques. The objec- tive of this study is to present the results of a systematic review of the scientific evidence about the efficiency of endoscopic saphenous vein harvest. Methods: We performed a systematic review in the bibliographical databases Pubmed, National Health Service Economic Evaluation Database, and NHS Health Technology Assess- ment Database. The search strategy was "endoscopic AND harvesting", in the period January 1970eDecember 2009. R…

medicine.medical_specialtyCost effectivenessCost-Benefit AnalysisGreater saphenous veinEfficiencyScientific evidenceVein harvestingmedicineEconomic evaluation databaseHumansSaphenous VeinEndoscopic harvestMedicine(all)business.industryGeneral surgeryHealth technologyEndoscopyEconomic evaluationSurgeryEconomic evaluationVein harvestTissue and Organ HarvestingSurgerybusinessCardiology and Cardiovascular MedicineVascular Surgical ProceduresEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Optimization of hepatitis C virus screening strategies by birth cohort in Italy

2020

Abstract Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strat…

medicine.medical_specialtyCost effectivenessCost-Benefit AnalysisHepatitis C virusSettore SECS-P/06cost-effectiveneHepacivirusmedicine.disease_causeAntiviral AgentsWorld healthNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMass Screeningcost-effectivenessAntibody screensHepatologyUnder-fivebusiness.industryscreeningHealth services researchhealthcost‐effectivenessHepatitis C ChronicHepatologyHepatitis CItaly030220 oncology & carcinogenesisSettore MED/42HCVOriginal Articleepidemiology030211 gastroenterology & hepatologyLiver Disease and Public HealthQuality-Adjusted Life YearsBirth cohortbusinessWHO targetscost-effectiveness HCV screening WHO targetsDemography
researchProduct

PIN31: THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HE…

2003

medicine.medical_specialtyCost effectivenessbusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthGastroenterologychemistry.chemical_compoundchemistryChronic hepatitisInternal medicinemedicinebusinessInterferon alfamedicine.drugPeginterferon alfa-2aValue in Health
researchProduct

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

2003

Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We u…

medicine.medical_specialtyCost effectivenessbusiness.industryRibavirinGastroenterologyvirus diseasesAlpha interferonHepatitis CWirtschaftswissenschaftenmedicine.diseaseGastroenterologySurgeryQuality-adjusted life yearClinical trialchemistry.chemical_compoundchemistryInternal medicinemedicinebusinessViral loadInterferon alfamedicine.drug
researchProduct

Effektivität einer universellen Varizellen-Schutzimpfung in Deutschland: Eine epidemiologische und gesundheitsökonomische Analyse

2006

Varicella is a highly contagious viral disease which mainly affects young children and usually is perceived as infection with a mild disease course. However, there is increasing evidence indicating that the morbidity and mortality as well as the economic impact associated with varicella are significant. While universal childhood vaccination against varicella is currently not recommended in Germany, the availability of safe and efficacious vaccines offers the opportunity for preventive intervention. Detailed and reliable data on the consequences of varicella and the possible impact of a universal vaccination program are missing to date for Germany. In order to generate this information, we c…

medicine.medical_specialtyCost effectivenessbusiness.industryvirusesvirus diseasesChildhood vaccinationVaricella vaccinationVirologyVaccinationEnvironmental healthPediatrics Perinatology and Child HealthEpidemiologymedicineEconomic analysisViral diseaseEconomic impact analysisbusinessKlinische Pädiatrie
researchProduct

Cost-effectiveness and cost-utility analysis of the treatment of emotional disorders in primary care: psicap clinical trial. description of the sub-s…

2018

Introduction: In the primary care (PC) setting in Spain, the prevalence of emotional disorders (EDs) such as anxiety, depression and somatoform disorder is high. In PC patients, these disorders are not always managed in accordance with the recommendations provided by clinical practice guidelines, resulting in major direct and indirect economic costs and suboptimal treatment outcomes. The aim is to analyze and compare the cost-effectiveness and cost-utility of group-based psychological therapy versus treatment as usual (TAU). Methods: Multicenter, randomized controlled trial involving 300 patients recruited from PC centers in Madrid, Spain, with symptoms or possible diagnosis of anxiety, moo…

medicine.medical_specialtyCost effectivenesslcsh:BF1-990QALYslaw.inventionprimary care03 medical and health sciencesIndirect costs0302 clinical medicineRandomized controlled triallawmedicinePsychologyClinical Study Protocol030212 general & internal medicinecost-utilityGeneral PsychologyCost–utility analysisEmocionstransdiagnostic cognitive-behavioral therapy030227 psychiatryPatient Health QuestionnaireClinical triallcsh:PsychologyMoodemotional disordersPhysical therapyAnxietymedicine.symptomPsychology
researchProduct

HCV eradication: a duty of the State, an option for the individual

2020

In recent years, the debate on ethical issues related to hepatitis C virus therapies has been focused on the problem of drug prices and access to therapies. Nonetheless, the goal of hepatitis C virus eradication set by the World Health Organization in 2016 is raising new ethical issues, since governments are faced with a new challenge: reaching through screening, diagnosis and treatment a large amount of subjects with undiagnosed hepatitis C infection. National governments, especially high-income countries with a Welfare State, are compelled to provide access to therapies, but also to involve those who are still unaware of their disease status. Since people cannot be forced but should be gu…

medicine.medical_specialtyCost effectivenessmedia_common.quotation_subjectHepatitis C virusmedicine.disease_causeSettore MED/02 - Storia Della Medicina03 medical and health sciences0302 clinical medicineState (polity)Settore MED/43 - Medicina Legalemedicinehcv030212 general & internal medicineEthicIntensive care medicineDutyAutonomymedia_commonEradicationEthical issuesbusiness.industryWelfare stateHepatitis Cmedicine.diseaseCost-effectivenessbusinessAutonomy
researchProduct